
The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US biotech M&A surge will indeed extend into Europe. The conversation touches upon the appetite for cross-border dealmaking, the growing role of private equity in European pharma and medtech, generational exits among family-owned pharma groups in Italy, and the role of digitalisation in all this. You can listen to episode 268 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Policy in Focus: What’s new with CMS drug price negotiation, with Alice Valder Curran

CAMP4 on a new class of ASO in gene under expression

Purespring on nephrology & gene therapy in kidney disease

Parexel: Flawless execution, policy shifts & patient-centric design
Free AI-powered recaps of pharmaphorum Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.